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ABSTRACT
Vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor for growth factors of the VEGF family. Endothelial cells express a membrane-bound and a soluble variant of this protein, the latter being mainly considered as a negative regulator of VEGF-A signaling. We previously reported that the soluble form is deposited in the extracellular matrix produced by endothelial cells in culture and is able to promote cell adhesion and migration through binding to α5β1 integrin. In this study, we demonstrate that the Ig-like domain II of VEGFR-1, which contains the binding determinants for the growth factors, is involved in the interaction with α5β1 integrin. To identify domain regions involved in integrin binding, we designed twelve peptides putatively mimicking the domain II surface and tested their ability to inhibit α5β1-mediated endothelial cell adhesion to soluble VEGFR-1 and directly support cell adhesion. One peptide endowed with both these properties was identified and shown to inhibit endothelial cell migration towards soluble VEGFR-1 as well. This peptide directly binds α5β1 integrin, but not VEGF-A, inducing endothelial cell tubule formation in vitro and neoangiogenesis in vivo. Alanine scanning mutagenesis of the peptide defined which residues were responsible for its biological activity and integrin binding.
INTRODUCTION
Vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor for members of the vascular endothelial growth factor (VEGF) family 1 . VEGFR-1 is closely related to the type III tyrosine kinase-Fms/Kit/platelet derived growth factor receptors, but it is classified into a distinct class of receptors whose extracellular region is composed of seven immunoglobulin (Ig)-like domains 2 . Ig-like domain II (dII) comprises the region involved in VEGF-A and placenta growth factor (PlGF) binding 3,4 , whereas Ig-like domains III and IV are involved in heparin binding, and domain III is also responsible for interaction with neuropilin-1 5 .
Studies carried out with PlGF, which is a VEGFR-1-selective ligand, indicated that the tyrosine kinase activity of this receptor is mostly required for adult pathological angiogenesis 6 . VEGFR-1 does not play a significative role in endothelial cell proliferation whereas its activation is greatly involved in chemotaxis of monocyte-macrophages 7 and in mobilization of endothelial and hematopoietic stem cells from the bone marrow 8,9 . Gene knockout studies demonstrated that VEGFR-1 is essential for the development and differentiation of embryonic vasculature, and that its inactivation results in increased hemangioblast commitment and disorganization of blood vessels 10,11 . However, mice carrying a homozygous deletion of the intracellular kinase domain show a correct blood vessel development, and a substantial impairment of monocyte-macrophages migration was the only reported phenotype 12 .
This result suggests that the extracellular region of VEGFR-1 is sufficient to support embryonic angiogenesis.
In addition to the transmembrane isoform of VEGFR-1 (tmVEGFR-1), endothelial cells (EC) produce a soluble form of the receptor, arising from alternative splicing of the same gene 13 .
Soluble VEGFR-1 (sVEGFR-1) comprises the first six Ig-like domains of the extracellular region of the receptor and a specific 30 amino acid tail at its C-terminus. Both isoforms bind VEGF-A with high affinity, and sVEGFR-1 acts as a potent antagonist of VEGF-A signaling by sequestering For personal use only. on April 15, 2017. by guest www.bloodjournal.org From 4 the growth factor and thereby inhibiting its interaction with the transmembrane receptors 14 . We previously demonstrated that sVEGFR-1 secreted by EC in culture becomes part of the extracellular matrix and is able to mediate EC adhesion through direct binding to α5β1 integrin 15 .
A key role of this integrin in promoting vasculogenesis and angiogenesis has been previously highlighted by the defective vascular phenotype of α5 knockout mice 16 and by the ability of either antibodies raised against this integrin or antagonist peptides to block in vitro and in vivo angiogenesis 17 .
Integrin binding to their ligands usually occurs through recognition of short amino acid sequences.
Many integrins, including α5β1, bind to arginine-glycine-aspartic acid (RGD) containing peptides, although other binding motifs have also been identified 18,19 . As none of the classic α5β1 integrin binding motifs is present in the sequence of sVEGFR-1, we investigated the molecular determinants responsible for sVEGFR-1/integrin interaction. We found that Ig-like dII of VEGFR-1 directly interacts with α5β1 integrin. Since this domain is also involved in growth factor binding, we tried to identify the domain regions specifically involved in integrin binding. We designed and tested twelve peptides putatively mimicking the domain surface and found one peptide able to inhibit α5β1-mediated endothelial cell adhesion to VEGFR-1 and directly support cell adhesion.
This peptide also inhibited endothelial cell migration towards sVEGFR-1 and induced endothelial cell tubule formation in vitro and neoangiogenesis in vivo. Finally, we performed alanine scanning mutagenesis of the peptide to define which residues were responsible for its biological activities and integrin binding.
METHODS
Reagents.
Recombinant human VEGFR-1/Fc, VEGF-A, and biotinylated VEGF-A were purchased from R&D Systems (Minneapolis, MN). The purified α5β1 integrin, octyl-β-D-glucopyranoside formulation, was from Chemicon. Peptide synthesis was carried out by PRIMM (Milan, Italy), and Antibodies used in this paper are detailed in Data Supplements.
Cell culture, cell adhesion and endothelial tubule formation. Human umbilical vein endothelial cells (HUVEC) were obtained and cultured as described 15 . A pool obtained from different individuals was used in all the experiments. Adhesion assays to recombinant proteins were performed as previously described 15 . Adhesion to peptides was carried out by using anhydride maleic activated microplates (Reacti-Bind, PIERCE, Rockford, IL) coated with 500 µg/ml of each peptide. In competition experiments, HUVEC were pre-incubated with 10 µg/ml antibody or 20 µg/ml peptide for 10 minutes at room temperature before plating and then allowed to adhere for 30 minutes at 37°C in the presence of the compounds. Where indicated, EDTA or EGTA (10 mM) were added at the time of plating. To assay for tubule formation, HUVEC were examined in a three-dimensional collagen gel in the presence or absence of proteins, peptides, or antibodies as previously described 20 .
Generation of recombinant Ig-like dII. The tmVEGFR-1 cDNA was kindly provided by Dr. M. Shibuya (Institute of Medical Science, University of Tokyo, Japan). The cDNA was modified to introduce a Kpn I site followed by a Kozak sequence, a start codon at the 5' end, a Bsi WI site followed by a HA Tag and a stop codon at the 3' end. The polylinker of the Baculovirus vector pFastBac 1 (Invitrogen-Life Technologies) was replaced by a linker containing a Kpn I and a Bsi WI site together with a His tag. The tmVEGFR-1 cDNA was first cloned into the pFastBac 1 vector using the Kpn I and Bsi WI sites. To construct the recombinant Ig-like dII, the signal sequence of VEGFR-1 was amplified by PCR using the oligonucleotides: 5'-GCGCGGATCCGGTACCGC-3' and 5'-GTGATGCGTACGTGAACCTGAACTAGATCCTGTG-3' and cloned into the modified pFastBac vector. Then the dII sequence was amplified with the oligonucleotides 5'-GTGATGCGTACGAGTGATACAGGTAGACCTTTC-3' and 5'-GTGATGCGTACGTCCGATTGTATTGGTTTGTCGATG-3'. The PCR fragment was cloned into Solid-phase binding assays. Integrin binding to recombinant proteins was assayed as previously described 15 . Interaction of peptides (500 µg/ml, coated on Reacti-Bind microplates) with the purified integrin was evaluated with a 1:100 dilution of the NKI-SAM 1 anti-α5 mAb followed by plate incubation with a biotinylated anti-mouse secondary antibody (Vector Laboratories Inc., Burlingame, CA). Streptavidin-alkaline phosphatase-conjugated and the appropriate substrate (4-nitrophenylphosphate, Roche Diagnostics, Basel, Switzerland) were then used for detection.
Absorbance was determined at 405 nm using a Microplate reader 3550-UV (Bio-Rad). In a different experiment, 500 µg/ml of peptide were coated on the Reacti-Bind microplates and interaction with VEGF-A was evaluated by incubating 200 ng of biotinylated VEGF-A on the plates. The amount of retained biotinylated VEGF-A was then determined ad described above.
Rabbit cornea assay. Angiogenesis was studied in the cornea of albino rabbits (Charles River, Immunofluorescence studies. Aliquots of Dynabeads M-270 Carboxylic Acid (Dynal Biotech, Oslo, Norway) were coated with the selected peptides as recommended by the manufacturer.
HUVEC were plated on fibronectin-coated coverslips and allowed to adhere for 2 hours in serumfree medium. Peptide-coated beads were then added for 30 minutes. Cells were washed with PBS, fixed with 3% formaldehyde in PBS, and permeabilized with 0.5% Triton X-100/PBS. Non specific staining was blocked with 3% BSA and coverslips were incubated with primary antibody against 
RESULTS
Ig-like dII of VEGFR-1 is involved in the interaction with α5β1 integrin.
We previously showed that purified α5β1 integrin binds to VEGFR-1/Fc protein, comprising the soluble receptor fused to the Fc domain of human IgG 15 . We also demonstrated that an antibody recognizing a peptide derived from Ig-like dII of VEGFR-1 competed with α5β1 integrin-mediated binding of EC to VEGFR-1 15 . In the present study, we analyzed the effect of this antibody on VEGFR-1/integrin interaction. In a solid-phase binding assay this antibody completely inhibited α5β1 binding to VEGFR-1/Fc (Fig. 1A ) whereas another pAb (Flt-1 H225) recognizing the extracellular domain of VEGFR-1 did not. As expected, no inhibition was observed using an antibody (Flt-1 C17) against the intracellular domain of VEGFR-1 (Fig. 1A) . We concluded that determinants for integrin binding were likely to be present within Ig-like dII.
Based on domain boundaries observed in the experimentally determined structures available from the PDB database (PDB IDs: 1flt, 1qty, 1rv6, 1qsv, 1qsz), we designed a recombinant protein corresponding to dII (residues 129-229). This protein was produced in the SF9 insect cell line using the Baculovirus-mediated expression system and was purified by affinity chromatography.
Recombinant dII was able to directly support HUVEC adhesion (Fig. 1B) , and to bind purified α5β1 integrin in a concentration-dependent manner (Fig. 1C ).
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From Design and experimental testing of peptides mapping on dII. Since VEGFR-1 Ig-like dII contains binding determinants for both growth factors of the VEGF family and α5β1 integrin, but neither VEGF-A nor PlGF compete with the interaction between VEGFR-1 and α5β1 integrin 15 , dII regions responsible for integrin and growth factor binding are expected not to be overlapping. To identify those regions specifically responsible for integrin binding, we took advantage of the domain structures determined by X-ray crystallography and available from the PDB database. The three-dimensional structures were examined to identify contiguous amino acid sequences that might mimic exposed regions of domain II. Twelve peptides (Table I) were designed according to the following criteria: i) they are on the protein surface (i.e., they have high overall solvent accessible surface area); ii) they correspond to different regions of the domain surface, covering it almost entirely; iii) they are shorter than 15 residues; iv) they contain polar residues and, whenever possible, residues charged at physiological pH values (Asp, Glu, Lys and Arg); v) they contain a low percentage of hydrophobic residues (i.e. Leu, Val, Ile, Met, Phe and Trp), to minimize solubility problems; vi) they do not contain Cys residues, which might lead to formation of dimeric peptides. To satisfy the last requirement, VEGFR-1 residue Cys158, which is involved in the formation of a disulfide bond within domain II structures, was replaced by Ala in peptide 4.
Additionally, to explore whether the presence of two branched hydrophobic residues next to each other might cause solubility problems, the adjacent Ile145 and Ile146 were both replaced by Thr in peptide 3. The sequence of peptide 5 has been previously published and reported to act as an angiogenesis inhibitor without binding to VEGF-A or inhibiting VEGF-A binding to its receptors 24 . The location of the different peptides on domain II structure is reported in Fig. 2A . To test the ability of the designed peptides to inhibit EC adhesion to VEGFR-1, each peptide was added to a HUVEC suspension before cell plating on VEGFR-1/Fc coated wells. As shown in Fig. 2B , peptides 4, 5, 7, and 12 effectively blocked EC adhesion to VEGFR-1/Fc. Moreover, peptides 4, 7, and 12 were able to partially inhibit EC adhesion to fibronectin, the canonical α5β1 integrin ligand, For personal use only. on April 15, 2017. by guest www.bloodjournal.org From suggesting that they might interfere with ligand binding sites of α5β1 integrin. However, when linked to microtiter plates, only peptide 12 directly supported EC adhesion (Fig. 2C) .
EC adhesion on peptide 12 was completely abolished by treatment with either EDTA or EGTA (Fig. 3A) indicating that this interaction required divalent cations, as it is generally the case for integrin binding to extracellular matrix proteins 18 . To demonstrate whether α5β1 integrin was indeed the protein mediating EC adhesion to peptide 12, we tested the effect of integrin-blocking antibodies. Pre-incubation of HUVEC with a mAb against α5β1 integrin inhibited cell adhesion to peptide 12, whereas a mAb against a different integrin subunit (α6) was ineffective (Fig. 3A) . In particular, when an anti-α5 subunit antibody was used, complete inhibition of EC adhesion was observed (Fig. 3A) .
Unligated integrins are diffusely distributed in the membrane but following ligand binding they are activated and form aggregates 25 . To examine whether peptide 12 was able to induce α5β1 integrin clustering upon binding, adherent HUVEC were incubated with magnetic beads coated with peptide 12, or with RGD or RGE peptides as positive and negative controls, respectively, and immunostained for α5β1 integrin (Fig. 3B) . A higher number of RGD-coated (Fig. 3B, panel b) than of peptide 12-coated beads (panel c) adhered to HUVEC, probably because of their interaction with other RGD-binding proteins on the cell surface. Indeed, a distinct staining for α5β1 was only observed around 66% of RGD-coated beads (panel d), supporting the idea that different ligands were involved in cell binding of these RGD-coated beads. On the other hand, 98% of peptide 12-coated beads (panel e) were immunostained with the anti-α5β1 integrin antibody, indicating that α5β1 integrin is the main cell ligand for this peptide. As expected, no RGE-coated beads attached to HUVEC in this assay (panel a).
Pre-incubation of HUVEC with peptide 12 completely abrogated the migration response towards VEGFR-1/Fc (Fig. 3C) , a process mediated by α5β1 integrin 15 . The inhibitory effect of peptide induced migration was observed (Data Supplements, Fig. S1 ). On the other hand, peptide 12 did not affect cell proliferation (data not shown).
Identification of peptide 12 residues involved in integrin binding. To assess the relative contribution given by peptide 12 residues to the interaction with α5β1 integrin, seven different peptides carrying a single substitution to Ala were synthesized. As shown in Fig. 4A , the ability of peptide 12 to support EC adhesion was significantly affected by single substitution of Leu221, His223 and, above all, Tyr220, with Ala. A "scrambled" peptide containing the same residues as peptide 12 in a different order (see Table 1 ) was used as a control and did not sustain cell adhesion.
As a direct confirmation of peptide 12/integrin interaction, we used a solid phase binding assay with wild-type and mutated peptides. In this assay, Tyr220, Leu221 and His223 were confirmed to be critical residues mediating peptide binding to purified α5β1 integrin (Fig. 4B) . Additionally, Arg224 was also shown to play an important role. The specific contribution of Arg224 in sustaining peptide binding to purified integrin might be due to a different conformation of the regions involved in peptide binding between purified and cell membrane integrin, possibly caused by interactions of the latter with other membrane proteins.
No significant interference with cell attachment or integrin binding was observed following substitution of Gln225, a VEGFR-1 residue known to be involved in VEGF-A binding 26 .
However, as other residues of peptide 12 are in contact with VEGF-A in the known structures of complexes with VEGFR-1, we analyzed whether peptide 12 was able to directly interact with VEGF-A. We also tested peptide 7, containing six residues of VEGFR-1 that interact with the growth factor, and peptide 1, mapping to a receptor region not involved in interactions with VEGF-A. The VEGFR-1/Fc protein was used as a positive control. As shown in Fig. 4C , VEGF-A did not bind to either peptide 12, 7 or 1 indicating that none of these peptides was sufficient to mediate VEGF-A binding.
For
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Peptide 12 supports in vitro and in vivo angiogenesis. The ability of peptide 12 to induce EC tubule formation was tested on a collagen I matrix and found to be similar to that of VEGF-A (Fig.   5 , panel a and b, respectively) when compared to unstimulated monolayer (no add). The Q225A peptide, which binds to α5β1 integrin and supports EC adhesion like peptide 12, also induced EC tubule formation (panel c). Conversely, treatment with the Y220A peptide, which does not bind α5β1 integrin, did not induce vessel shaping (panel d). As a control of specificity, tubule formation assay was performed using peptide 12 previously incubated with an antibody specifically recognizing its amino acid sequence. In this case, formation of capillary structures was not observed (panel e).
To evaluate a possible role of VEGF in peptide 12-mediated vessel shaping, tubule formation assay was also performed in the presence of function blocking antibodies against VEGFR-1 or of VEGFR-1/Fc chimera. In these experiments, addition of peptide 12 partially restored EC growth and vessel shaping (Data Supplements, Fig. S2 ), suggesting that this peptide acted through a mechanism parallel to that of VEGF.
To address the significance of the above findings in vivo, pellets releasing peptide 12 were implanted into avascular rabbit corneas and neovascularization was monitored for 17 days. As shown in Fig 6A, peptide 12 (100 µg/pellet) strongly promoted angiogenesis. Extent, growth rate, and pattern of capillary growth, reported as angiogenic score in Fig. 6B , overlapped with that obtained with VEGF-A (400 ng/pellet). Consistent with the in vitro data, the control Y220A peptide lacked angiogenic activity. Results obtained with two different concentrations of peptide 12, 10 µg and 100 µg/pellet, indicated that angiogenesis was sustained in a dose-dependent manner (Table II) Fig. 7A and B, adhesion on peptide 12 did not promote FAK phosphorylation and did not result in significant extracellular signal-regulated kinase (ERK1/2) phosphorylation, the latter being a downstream effector of both integrins and growth factor receptors. ERK1/2 phosphorylation was observed in EC adhering on peptide 12 in the presence of VEGF-A. On the other hand, phosphorylation of Shc could be observed in HUVEC adhering on fibronectin and on peptide 12 in the absence of exogenous VEGF-A (Fig. 7C) .
Formation of membrane macromolecular complexes between integrins and growth factor receptors has been previously highlighted 29 . In particular, a recent study on acute myeloid leukemia cell lines revealed an association between tmVEGFR-1, integrin β1, and human ERG K + channel 30 .
We investigated whether also in HUVEC β1 integrin could form a complex with tmVEGFR-1 but co-immunoprecipitation analysis could not reveal any interaction (Data Supplements, Fig. S6A ).
For personal use only. on April 15, 2017. by guest www.bloodjournal.org From Moreover, expression of the mRNA coding for human ERG-1 protein was not observed in HUVEC (Fig. S6B) .
DISCUSSION
Soluble VEGFR-1 can play two opposite biological roles. It can act both as a negative regulator of VEGF-related growth factor signaling 13 and as an extracellular matrix protein involved in endothelial cell adhesion and migration 15 . To completely understand the angiogenesis and vasculogenesis processes, it is of primary importance to define when and where this molecule behaves as a positive or a negative regulator of angiogenesis.
We previously reported that the involvement of sVEGFR-1 in cell adhesion and migration relies on its interaction with α5β1 integrin. In this study, we show that a peptide, isolated from VEGFR-1, is able to bind and activate α5β1 integrin.
Firstly we demonstrated that Ig-like dII of sVEGFR-1 is involved in the interaction with the integrin. To identify dII regions mediating this interaction, we tested twelve different peptides mimicking most of the dII surface and found that four of them inhibited cell adhesion to sVEGFR-1. Of these, peptides 4 and 12 are situated on opposite sides of the domain, each on one of the two β-sheets packed face-to-face, while peptide 7 lies on a plane roughly perpendicular to the two β-sheets. Only peptide 5 is relatively close to both peptide 7, partially overlapping with it, and peptide 12, which is situated on the same β-sheet. The relatively distant position of these peptides suggests that their interference with cell adhesion to sVEGFR-1 may be achieved through interaction with different binding partners and diverse mechanisms. Accordingly, peptide 12 is the only one in our series that directly supported EC adhesion, providing us with the first indication that this peptide may directly interact with α5β1 integrin. EC binding to peptide 12 was divalent cation-sensitive and antibodies against α5β1 integrin specifically blocked this interaction, supporting the assumption that EC adhesion to peptide 12 was α5β1 integrin-mediated. In particular, our results In addition to these indirect observations, we also detected a direct interaction between α5β1 integrin and peptide 12 in a solid phase binding assay. Alanine-scanning mutagenesis identified four residues of peptide 12, namely Tyr220 (giving the highest contribution), Leu221, His223 and Arg224 that, if mutated, significantly reduced peptide ability to support direct interaction with α5β1 integrin and, with the exception of Arg224, cell adhesion. This YLXHR motif shows some similarities but also noticeable differences with previously described α5β1 integrin binding sequences 18,19 . Similarly to the RGD motif, the fibronectin PHSRN and VKNEED synergy sites, and the majority of peptide sequences identified from phage library screenings 31,32 , the YLXHR motif bears a positive charge, which can be contributed either by the Arg or His residue. Moreover, similarly to many peptide sequences selected from phage libraries, it contains an aromatic residue (Tyr) separated by two or three amino acids from the positively charged one. However, this motif differs from those previously identified in the position of the aromatic and positive residues (RXXXW being the most typical arrangement) and in the role played by the hydrophobic residue Leu. Additionally, this is the first motif for which an aromatic residue, rather than a charged one, plays the most important role for α5β1 integrin binding.
We demonstrated that peptide 12 induces tubule-like structures formation in an in vitro angiogenic assay and supports neoangiogenesis in vivo.
Interestingly, addition of peptide 12 in the in vitro vessel formation assay circumvents the effects of either sVEGFR-1 or anti-VEGFR-1 function-blocking antibodies, partially restoring EC survival and tubule structuring. These data suggest that peptide 12 activates a signal pathway parallel to that of VEGF-A. Accordingly, peptide 12 enhances the angiogenic effect of VEGF-A in vivo.
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Peptide 12 plausibly exerts these pro-angiogenic properties through integrin binding and activation of an α5β1-mediated signaling pathway, since this peptide is not able to directly bind VEGF-A, its tyrosine kinase receptors, or other molecules involved in VEGFR signaling such as neuropilins (our unpublished data). We analyzed whether α5β1 binding to peptide 12 induced FAK phosphorylation, the main signaling mechanism of α5β1 integrin following fibronectin binding, but no FAK phosphorylation could be observed. At the same time point, ERK phosphorylation was detected in EC adhering on peptide 12 only in the presence of VEGF-A. On the other hand, we could show a slight phosphorylation of the adaptor protein Shc 28 in the absence of exogenous VEGF-A. It remains to be clarified whether Shc phosphorylation induced by peptide 12 requires further VEGF-induced signaling to result into ERK phosphorylation.
Interestingly, peptide 12 angiogenic activity in vivo was significantly impaired by both Bevacizumab, a monoclonal antibody that blocks VEGF-A binding to its receptors, and Sunitinib, a tyrosine kinase inhibitor acting also on VEGFRs. These results suggest that peptide 12 interactions with α5β1 integrin requires simultaneous VEGF-A activation of its transmembrane receptors to give neoangiogenesis. Alternatively, peptide 12 requires "active" endothelial cells, as those stimulated by VEGF-A, to operate through α5β1 integrin. It should be consider that VEGF-A elicits different functions in endothelium homeostasis, several of which we are just beginning to understood 33 .
It has been previously reported that cross talk between integrins and growth factors represents an important modulator of vasculogenesis and angiogenesis 29 . Significant enhancement of the angiogenic response can be specifically observed when both α5β1 integrin and VEGF-A receptors are engaged 34 . In this perspective, we also investigated whether peptide 12 could directly interact with tmVEGFR-1 but we did not detect any interaction in co-immunoprecipitation studies.
Moreover, previous studies could not detect the formation of a macromolecular complex involving α5β1 integrin and VEGFR-2 35 . Nevertheless, an additional transmembrane receptor could 
